Welcome to the official documentation for LeukemiaBD, a comprehensive, manually curated resource of potential biomarker candidates for leukemia. Biomarkers are essential for the effective management of leukemia, providing critical information for early detection, monitoring disease progression, and predicting treatment outcomes.
##Citation zonedo:-(https://doi.org/10.5281/zenodo.20094997)
LeukemiaBD was developed to provide a centralized repository for researchers and clinicians studying leukemia biomarkers. The data is curated from extensive research to assist in identifying and validating unique markers across various leukemia subtypes.
- Total Entries: 1895 entries representing potential biomarker candidates.
- Curation Source: Information is compiled from 470 relevant research papers.
- Unique Candidates: The resource features approximately 1568 unique biomarkers or biomarker candidates.
The database categorizes biomarkers into three functional types based on their clinical utility:
- Diagnostic (59.1%): 1519 markers used for the identification and classification of leukemia.
- Prognostic (34.1%): 855 markers used to predict the likely course and outcome of the disease.
- Predictive (6.8%): 115 markers used to predict a patient's likely response to a specific therapy.
LeukemiaBD includes a wide array of biomolecules that serve as biomarkers:
- RNA (54.1%): The most prevalent biomolecule type in the database.
- Proteins (23.1%): Critical markers for functional cellular analysis.
- miRNA (19.4%): Important regulators often found to be dysregulated in cancer.
- DNA (2.6%): Includes mutational and structural variants.
- lncRNA (0.6%) and Metabolites (0.2%): Emerging classes of leukemia biomarkers.
Biomarkers in the database have been identified and validated across various biological sources:
- Blood: 904 biomarkers extracted from blood samples.
- Bone Marrow: 777 biomarkers identified in bone marrow specimens.
- Cell Lines: 234 biomarkers validated in experimental cell line models.
- Other Sources: Includes Serum (76), Tissues (77), and more.
- Biomarker Discovery: Providing a rich dataset for the identification of novel leukemia signatures.
- Clinical Research: Assisting in the development of diagnostic kits and targeted therapies based on specific molecular profiles.
- Data Mining: Serving as a high-quality resource for bioinformatics analysis and structural studies of leukemic variations.
This resource is open-access and distributed under standard research terms, permitting use for scientific advancement provided the original work is properly credited.